Home > Cardiology > SGLT2 inhibitors cardioprotective even without diabetes

SGLT2 inhibitors cardioprotective even without diabetes


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Annals of Internal Medicine
Reuters Health - 11/04/2022 - Treatment with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) may help keep people with heart failure (HF) out of the hospital and offer protection against cardiovascular disease, regardless of the presence of diabetes, a new analysis shows. Randomized controlled trials have established the cardiac protection of SGLT2i therapy for adults with type 2 diabetes and new evidence suggests that these results could extend to people without diabetes as well. To investigate further, researchers from China did a systemic review and meta-analysis of eight randomized controlled trials that evaluated the effect of dapagliflozin, empagliflozin, or canagliflozin in patients with HF regardless of the presence of type 2 diabetes. Altogether, the trials had 15,022 participants. SGLT2i therapy reduced HF hospitalization by 37% at six months, 32% at one year, and 26% at two years - all with "high certainty" evidence, they report in the Annals o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on